Lake Street Reiterates Rating on KZIA $KZIA
Key Points
- Lake Street now rates Kazia Therapeutics Limited ($KZIA) "buy" with a $32 target.
- Lake Street's $32 price target implies 153.77% upside from Kazia Therapeutics Limited's ($KZIA) current $12.61 share price.
- The Street's average $KZIA price target is $28.44.
- $KZIA last traded around $12.61.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Lake Street reiterated its rating on Kazia Therapeutics Limited ($KZIA) to a "buy" rating in a recent research note and set a price target of $32, a 153.77% upside from the current price.
Kazia Therapeutics Limited Stock Down 7.1%
Shares of Kazia Therapeutics Limited ($KZIA) traded around $12.61 on Saturday, down 7.1% for the day.
Kazia Therapeutics Limited Earnings
Analysts Set New Price Targets
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Get Kazia Therapeutics Limited alerts
New 13F filings, insider trades, and analyst moves on $KZIA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.